Tempur Sealy insider plans $6.05M sale of 77,079 TPX shares
Rhea-AI Filing Summary
Tempur Sealy International (TPX) submitted a Form 144 notice reporting a proposed sale of 77,079 common shares with an aggregate market value of $6,054,108.39. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 08/13/2025.
The filing shows the shares were acquired as Performance Stock Units in three tranches on 01/03/2024, 01/04/2024 and 01/04/2022 and were paid as compensation. The notice reports no securities sold in the past three months and includes the filer’s attestation that they are not aware of any undisclosed material adverse information.
Positive
- None.
Negative
- Proposed sale of 77,079 shares valued at $6,054,108.39 is planned to be executed on 08/13/2025 via Morgan Stanley Smith Barney LLC.
- Insider monetization of shares issued as Performance Stock Units is disclosed, which could increase share supply available for trading on the announced date.
Insights
TL;DR: Proposed sale of 77,079 TPX shares (~$6.05M), ~0.037% of outstanding; modest market impact.
The Form 144 discloses a planned sale of 77,079 common shares for an aggregate value of $6,054,108.39 through Morgan Stanley on the NYSE, with an approximate sale date of 08/13/2025. The shares match three acquisition tranches of Performance Stock Units paid as compensation, indicating the sale arises from previously issued equity awards rather than an open-market issuance. Given the share count relative to the reported 209,888,100 outstanding shares, this filing by itself is unlikely to materially affect the company’s market capitalization.
TL;DR: Sale consists of vested Performance Stock Units paid as compensation; filing signals insider monetization and should be tracked with future disclosures.
The document shows the securities to be sold were acquired as Performance Stock Units on 01/03/2024, 01/04/2024 and 01/04/2022 and that payment was recorded as compensation. The filer also affirms no undisclosed material adverse information. For governance review, this is a routine disclosure of insider monetization of compensation awards; any interpretation of motives or broader governance implications would require additional filings or statements not contained here.